Drug Wholesalers and the Generic Price War

While the drug wholesaling industry appears reasonably healthy right now, the ongoing generic drug price war among retail pharmacies will create the risk of reduced wholesaler profitability. Understanding this dynamic is crucial for predicting the future of wholesaler relationships with […]

Read More

Reshaping Biotechnology’s Financing Relay Race

Biotech’s current funding crisis is unlike any previous funding challenge the sector has faced. In the past, funding droughts were largely driven by investor sentiment toward the biotech industry. When investors were bullish about the sector’s prospects — for instance, […]

Read More

Comparative Effectiveness: Tools, Not Rules

The topic of comparative effectiveness research (CER) took off with a bang as the Obama Administration boosted funding for the activity in its January stimulus package by $1.1 billion, as reported in last month’s issue. Commentary from Washington officials and […]

Read More

Drug Wholesalers and the Generic Price War

While the drug wholesaling industry appears reasonably healthy right now, the ongoing generic drug price war among retail pharmacies will create the risk of reduced wholesaler profitability. Understanding this dynamic is crucial for predicting the future of wholesaler relationships with […]

Read More

In Defense of Sales Reps

April has brought yet more news about layoffs in pharma—the most recent being Johnson & Johnson announcing a 6% reduction, specifically of sales and marketing people. There have been too many headlines to count about staff reductions across the board […]

Read More

Pharma 2020: Marketing the Future

In the 1990s, most of the medicines Pharma made were primary-care therapies for diseases afflicting large patient populations, such as hypertension, diabetes, high cholesterol and depression. But genomics, proteomics and metabolomics are providing new tools with which to develop larger […]

Read More